Cart0

Tirzepatide, 40 mg, in a ready-to-use pen. Tirzepatide is a dual agonist stimulating the GLP-1 and GIP receptors at once, and in registered form a prescription medicine.

What is in this box

A pen already filled with tirzepatide solution, 40 mg in total, and six replaceable needles. Most of this catalogue, including the other two tirzepatide versions, comes as dry powder that has to be dissolved, calculated and measured against the scale of a syringe. The pen skips that stage: the liquid is ready from the start and the amount is set with the dial on the pen body.

Six needles do not mean six administrations. A needle is used once and changed every time, and how many administrations the pen gives depends on the amount taken each time. Further needles are bought separately, as with insulin pens.

Pen or vial

This pen 20 mg vial of powder
Preparation none, the solution is ready dissolving and mixing
Measuring dial on the pen body scale of an insulin syringe
Risk of a conversion error none, there is nothing to convert real, a unit is not a millilitre
Amount 40 mg 20 mg
Price per milligram lower higher

The pen costs more in total and less per milligram: twice the amount for less than twice the price of a 20 mg vial. The current prices of all three versions are in the purchase boxes on the Tirzepatide page.

Storing a ready solution

A ready solution is less stable than dry powder, and that is the other side of the convenience. The pen is kept in the fridge, away from light, and must not be frozen. Powder in a vial tolerates room conditions better for as long as it stays dry. The general rules are in the guide on storage.

Nouveaux Ltd. as the manufacturer

Nouveaux Ltd. has the narrowest catalogue of the three brands and the largest containers. It is the only one here supplying tirzepatide and retatrutide in a ready pen, and its BPC-157 20 mg, CJC-1295 10 mg, sermorelin 10 mg, PEG-MGF 10 mg and follistatin 2 mg come from no other brand we stock. The code from the box is checked in the manufacturer's own tool at nouveauxltd.com.

What the evidence says

In SURMOUNT-1 at 15 mg tirzepatide reduced body weight by 20.9 percent over 72 weeks against 3.1 percent on placebo, and in SURMOUNT-5, the head-to-head trial in obesity without diabetes, it reached 20.2 percent against 13.7 percent for semaglutide. The full account, with the sources and the limits, is on the Tirzepatide page, and the background in the guide on why tirzepatide acts on two receptors.

We publish no dosing schedules. Sold as research material, not as a medicine, and not the registered product Mounjaro.

This pen next to the other Tirzepatide versions

The same molecule is sold here as powder in two 20 mg vials: Genheal, 20 mg with one solvent ampoule and Bio-Peptide, 20 mg with two. A vial is the smaller purchase to start with; the pen is the one without reconstitution and with the lowest price per milligram.

Also from Nouveaux Ltd. in this group

Within Weight loss peptides, Nouveaux Ltd. also supplies Retatrutide 40 mg Quick Pen and HGH Fragment 176-191 10 mg.

Sleep apnoea: what the SURMOUNT-OSA trial showed

Tirzepatide is the active substance of the drug Mounjaro. The numbers below come from clinical studies of that drug, run under medical supervision. The research material in this pen is not the drug and has neither its label nor its quality control.

SURMOUNT-OSA consists of two phase 3 trials in 469 adults with obesity and moderate or severe sleep apnoea, without diabetes. The results were published in the New England Journal of Medicine in 2024. The severity of apnoea is measured by the AHI, the number of pauses and shallow breaths per hour of sleep.

Result after 52 weeks Tirzepatide Placebo
Change in AHI, trials 1 and 2 minus 50.7 and 58.7 percent minus 3.0 and 2.5 percent
Mild apnoea without sleepiness, or resolution 42.2 and 50.2 percent of people 15.9 and 14.3 percent of people
Change in body weight minus 17.7 and 19.6 percent minus 1.6 and 2.3 percent
Systolic blood pressure after 48 weeks minus 9.5 and 7.6 mm Hg minus 1.8 and 3.9 mm Hg

At the start, participants had about 50 apnoea events per hour on average and weighed about 115 kg. Trial 2 enrolled people who used a CPAP machine throughout. 91.5 percent of people on tirzepatide and 74.4 percent on placebo stayed to the end.

Not only weight loss

An analysis published in 2026 in Nature Medicine looked at where the improvement comes from. Better breathing and oxygenation at night lowered CRP, insulin resistance and triglycerides independently of the fall in body weight. Participants also rated their sleep clearly better than people on placebo. Dosing in these studies was set by the drug's protocol, and choosing a dose is a matter for a doctor. All the results are described in the guide Tirzepatide and sleep apnoea.

Sources: Malhotra et al., New England Journal of Medicine 2024, Malhotra et al., Nature Medicine 2026.

Questions

Does the pen need preparing?

No. The solution is ready, so there is no powder to dissolve and no concentration to work out.

How much tirzepatide is in the pen?

40 mg, twice as much as the 20 mg vials sold here.

Do six needles mean six administrations?

No. A needle is used once, and the number of administrations depends on the amount taken each time. Further needles are bought separately.

How do I check that a Nouveaux Ltd. product is genuine?

Enter the code from the box in the checker on nouveauxltd.com.

Delivery

We ship within Poland and abroad. Outside Poland shipping costs 30 EUR paid in advance or 80 EUR cash on delivery, the same for every country: shipping and payments. How to check the code on each brand is described in check your product.